21 April 2021 | News
Licensed for commercialisation to the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA
IIT Kharagpur (Kgp) has successfully commercialized its flagship healthcare product – COVIRAP – the novel diagnostic technology for infectious diseases including COVID-19 and beyond.
The product developed by lead researchers Professor Suman Chakraborty, Dr. Arindam Mondal and their research group has been licensed for commercialization to the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA.
Bramerton Holdings has signed a record deal for securing global rights for commercially disseminating the COVIRAP technology developed at IIT Kharagpur in various geographical locations outside the territory of the Indian subcontinent. Rapid Diagnostic has also initiated adapting the COVIRAP technology platform for COVID-19 and tuberculosis, in collaboration with IIT Kharagpur.
The research team has now developed a more advanced version of COVIRAP using a step-wise isothermal nucleic acid testing technology for the rapid diagnostics of pathogenic infections including SARS-CoV-2 in individuals.
The COVID-19 diagnostic test can be conducted directly from human swab samples in the portable device developed by the team, without requiring any separate facility for RNA extraction. The results can be made available within 45 minutes of obtaining the patient sample.
The kit has also been also supplemented with a free smartphone app to facilitate unambiguous results interpretation and automated dissemination to the patients.
Commercialization and use in the USA and Europe under the Emergency Use Authorization (EUA) process are currently underway. Both the Rapid Diagnostic Group in India and Bramerton Holdings in the USA, in association with IIT Kharagpur, have already identified the key resources towards establishing the reagent supply chain, kit and device manufacturing in entirety under a ‘Make in India’ initiative with complete import substitution.